Lexicon - endlich aufwärts? - 500 Beiträge pro Seite
eröffnet am 23.02.06 10:31:41 von
neuester Beitrag 20.03.06 18:01:14 von
neuester Beitrag 20.03.06 18:01:14 von
Beiträge: 6
ID: 1.042.591
ID: 1.042.591
Aufrufe heute: 0
Gesamt: 875
Gesamt: 875
Aktive User: 0
ISIN: US5288723027 · WKN: A14SSK · Symbol: LXRX
1,9400
USD
+1,04 %
+0,0200 USD
Letzter Kurs 22:00:00 Nasdaq
Neuigkeiten
14.05.24 · globenewswire  |
09.05.24 · globenewswire |
02.05.24 · globenewswire |
29.04.24 · globenewswire |
29.04.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5100 | +24,39 | |
| 3,1700 | +23,59 | |
| 3,1100 | +21,01 | |
| 0,8200 | +18,84 | |
| 0,7300 | +18,47 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 11,900 | -15,90 | |
| 1,7700 | -16,11 | |
| 0,5350 | -20,15 | |
| 0,7755 | -30,39 | |
| 0,7800 | -65,64 |
Feedback
Leider gibt es zu Lexicon hier schon lange keine Beiträge mehr.
Charttechnisch sollte es nun doch aufwärts gehen, soweit ich den Chart "lesen" kann, oder?
Hat jemand fundmentale Daten?
Danke für Antworten!
Meixnel
Charttechnisch sollte es nun doch aufwärts gehen, soweit ich den Chart "lesen" kann, oder?
Hat jemand fundmentale Daten?
Danke für Antworten!
Meixnel
22.02.2006 13:34
Lexicon Genetics Reports 2005 Fourth Quarter and Full Year Financial Results; Lexicon Achieves 23% Annual Revenue Growth
THE WOODLANDS, Texas, Feb. 22 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nachrichten) , a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today reported financial results for the three months and year ended December 31, 2005.
"In 2005, we made significant progress toward our goal of entering clinical development with our internal programs," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer. "We continue to be encouraged by the results of preclinical safety testing for our lead programs -- LG617 for Alzheimer`s and cognitive disorders and LG103 for irritable bowel syndrome."
Revenues: Lexicon`s revenues for the three months ended December 31, 2005 increased 30 percent to $33.9 million from $26.0 million for the corresponding period in 2004. The increase was primarily attributable to Lexicon`s completion of two performance milestones related to work it is doing in collaboration with Genentech, Inc. that resulted in payments from Genentech totaling $20 million. Revenue recognized under Lexicon`s alliance with Organon and its award from the Texas Enterprise Fund also contributed to the increase in revenue. Revenue in the fourth quarter of 2004 included performance milestone payments from Genentech and Takeda Pharmaceutical Company Limited. For the year ended December 31, 2005, revenues increased 23 percent to $75.7 million from $61.7 million in 2004.
Research and Development Expenses: Research and development expenses for the three months ended December 31, 2005 increased three percent to $23.9 million from $23.1 million for the corresponding period in 2004. For the year ended December 31, 2005, research and development expenses increased three percent to $93.6 million from $90.6 million in 2004.
General and Administrative Expenses: General and administrative expenses for the three months ended December 31, 2005 were $4.3 million, substantially unchanged from the corresponding period in 2004. For the year ended December 31, 2005, general and administrative expenses decreased two percent to $18.2 million from $18.6 million in 2004.
Net Income (Loss): Net income for the three months ended December 31, 2005 was $5.9 million, or $0.09 per share, principally as a result of the performance milestone payments received in the fourth quarter of 2005. This compares favorably to a net loss of $0.5 million, or $0.01 per share, for the corresponding period in 2004. The net loss for the year ended December 31, 2005 decreased to $36.3 million, or $0.57 per share, from a net loss of $47.2 million, or $0.74 per share in 2004.
Cash and Investments: As of December 31, 2005, Lexicon had $99.7 million in cash and investments, including restricted cash and investments, as compared to $90.2 million as of September 30, 2005 and $87.6 million as of December 31, 2004. Cash and investments at December 31, 2005 reflected the receipt in December 2005 of an up-front payment, performance milestones and research funding pursuant to Lexicon`s alliance with Genentech.
"Our financial and business development efforts were highly successful in 2005," said Julia P. Gregory, Lexicon`s executive vice president, corporate development and chief financial officer. "We continue to create long-term value through our alliances, with immediate positive impact on our revenues and cash position. Strategic collaborations and technology contracts and licenses brought in more than $120 million in cash to Lexicon in 2005, thereby providing a strong source of funding during the year."
Year 2005 Highlights
Expansion of alliance with Genentech: In December 2005, Lexicon announced the expansion of its drug discovery alliance with Genentech to include the advanced research, development and commercialization of new biologic drugs. Lexicon will receive a total of $25 million in upfront and milestone payments and research funding during the three-year advanced research portion of the expanded alliance. In this period, Lexicon will conduct advanced research on a broad subset of targets included in Genentech`s Secreted Protein Discovery Initiative (SPDI) program and validated using Lexicon`s proprietary gene knockout technology.
Lexicon may develop and commercialize drugs for up to six of the targets included in the alliance. Genentech retains an option on the potential development and commercialization of these drugs under a cost and profit sharing arrangement, with Lexicon having certain conditional rights to co- promote drugs on a worldwide basis. Genentech is entitled to receive milestone payments in the event of regulatory approval and royalties on net sales of products commercialized by Lexicon outside of a cost and profit sharing arrangement. Lexicon will receive payments from Genentech upon achievement of milestones related to the development and regulatory approval of certain drugs resulting from the alliance that are developed and commercialized by Genentech. Lexicon is also entitled to receive royalties on net sales of these products, provided they are not included in a cost and profit sharing arrangement.
Completion of two performance milestones in Genentech collaboration: Lexicon completed two performance milestones related to work it is doing in collaboration with Genentech and received corresponding payments totaling $20 million. The first of these milestones related to the completion by Lexicon of the analysis of the physiological and behavioral functions of the final set of targets selected from Genentech`s SPDI program under the companies` initial collaboration. The second related to the delivery of data from advanced research already conducted by Lexicon under the expanded alliance.
Alliance with Organon to develop biotherapeutic drugs: In May 2005, Lexicon and Organon, the human healthcare business of Akzo Nobel, announced the formation of a collaboration to jointly discover, develop and commercialize novel biotherapeutics. The alliance encompasses up to 300 genes encoding secreted proteins or potential antibody targets that were jointly selected for the collaboration, including two of Lexicon`s existing biotherapeutics discovery programs. Organon and Lexicon will share costs and responsibility for research, preclinical and clinical activities and will equally benefit from collaboration product revenue. Lexicon received an upfront payment of $22.5 million from Organon in exchange for access to Lexicon`s drug target discovery capabilities and the exclusive right to co- develop biotherapeutic products that modulate the 300 genes selected for the collaboration. Organon will also provide research funding totaling up to $50 million to Lexicon for Organon`s 50% share of the collaboration`s costs during the four-year target function discovery portion of the alliance.
Alliance with XOMA for antibody drug development and commercialization: In June 2005, Lexicon established an alliance with XOMA Ltd. to jointly develop and commercialize antibody drugs for certain targets discovered by Lexicon. During the three-year initial term of the alliance, Lexicon will select at least three targets for submission to the collaboration and XOMA will generate or engineer antibodies that modulate the collaboration`s targets using phage display libraries and its proprietary Human Engineering(TM) technology. Lexicon and XOMA will jointly develop and commercialize novel antibodies directed at these targets and will share the responsibility and costs for research, preclinical, clinical and commercialization activities. Costs and profits will be allocated 65% to Lexicon and 35% to XOMA.
Award from Texas Enterprise Fund: In July 2005, Lexicon announced it was awarded $35 million from the Texas Enterprise Fund for the creation of a knockout mouse embryonic stem cell library containing 350,000 cell lines. Lexicon is creating this new library using its proprietary gene trapping technology for the Texas Institute for Genomic Medicine, a newly formed non- profit institute. In addition, Lexicon will equip the institute with the bioinformatics software required for the management and analysis of data relating to the library.
Contract with National Institutes of Health: In September 2005, Lexicon entered into a three-year contract to provide selected knockout mouse lines and related phenotypic data to the United States National Institutes of Health (NIH). These materials are related to genes that have already been knocked out and analyzed by Lexicon. Lexicon will receive payment from NIH of approximately $4.9 million for NIH`s initial order of knockout mouse lines. Lexicon retains the sole right to provide these materials to commercial entities.
Harvested novel discoveries from Genome5000(TM) program: Lexicon`s Genome5000 program continued to yield new biologically-validated targets for drug discovery. In this program, Lexicon is analyzing 5,000 genes using its proprietary gene knockout technologies and its extensive physiological and behavioral analyses to discover new drug targets from the human genome. To date, Lexicon has completed the analysis of more than sixty percent of these genes and has harvested more than 90 promising targets related to major medical needs.
Lexicon Conference Call:
Dr. Arthur T. Sands and Julia P. Gregory will host a conference call at 11:00 a.m. Eastern Time on Wednesday, February 22, 2006 to review Lexicon`s operating highlights and its financial results for the year ended December 31, 2005 and to discuss the company`s guidance for 2006.
The dial-in number for the conference call is 800-946-0741 (within the United States) or 719-457-2649 (international). The pass code for all callers is 7195604. Investors can access http://www.lexicon-genetics.com/ to listen to a live webcast of the call. The webcast will be archived and available for review through February 27, 2006.
About Lexicon Genetics
Lexicon Genetics is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon is systematically discovering the physiological and behavioral functions of genes to identify potential points of therapeutic intervention, or drug targets. Lexicon makes these discoveries using its proprietary gene knockout technology to model the physiological effects that could be expected from prospective drugs directed against novel targets. The Company has advanced knockout- validated targets into drug discovery programs in six therapeutic areas: diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. Lexicon is working both independently and through strategic collaborations and alliances to accelerate the development and commercialization of its discoveries. Additional information about Lexicon is available through its corporate website, http://www.lexicon-genetics.com/ .
Safe Harbor Statement
This press release contains "forward-looking statements," including statements about Lexicon`s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management`s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon`s ability to successfully conduct preclinical development of its drug candidates and advance such candidates into clinical development, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as those relating to manufacturing, the regulatory process, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon`s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Business - Risk Factors" in Lexicon`s annual report on Form 10-K for the year ended December 31, 2004, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Lexicon Genetics Incorporated Selected Financial Data Consolidated Statements of Operations Data Three Months Ended Year Ended (In thousands, except December 31, December 31, per share data) 2005 2004 2005 2004 (unaudited) (unaudited) Revenues: Collaborative research $33,393 $21,739 $69,567 $49,736 Subscription and license fees 501 4,272 6,113 12,004 Total revenues 33,894 26,011 75,680 61,740 Operating expenses: Research and development 23,854 23,120 93,625 90,586 General and administrative 4,318 4,349 18,174 18,608 Total operating expenses 28,172 27,469 111,799 109,194 Income (loss) from operations 5,722 (1,458) (36,119) (47,454) Interest income 881 440 2,645 1,638 Interest expense (815) (831) (3,280) (2,660) Other income, net 245 1,308 558 1,304 Income (loss) before taxes 6,033 (541) 36,196 47,172 Income tax provision 119 --- 119 --- Net income (loss) $5,914 $(541) $(36,315) $(47,172) Net income (loss) per common share, basic and diluted $0.09 $(0.01) $(0.57) $(0.74) Shares used in computing net income (loss) per common share, basic 64,539 63,449 63,962 63,327 Shares used in computing net income (loss) per common share, diluted 67,317 63,449 63,962 63,327 Consolidated Balance Sheet Data As of As of December 31, December 31, (In thousands) 2005 2004 (unaudited) Cash and investments, including restricted cash and investments of $430 $99,695 $87,558 Property and equipment, net 85,265 84,573 Goodwill 25,798 25,798 Intangible assets other than goodwill, net 640 1,840 Total assets 218,714 211,980 Deferred revenue 81,582 37,592 Current and long-term debt 36,940 37,631 Accumulated deficit (297,430) (261,115) Total stockholders` equity 85,802 121,594
FCMN Contact: bfaulkner@lexgen.com
Lexicon Genetics Reports 2005 Fourth Quarter and Full Year Financial Results; Lexicon Achieves 23% Annual Revenue Growth
THE WOODLANDS, Texas, Feb. 22 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nachrichten) , a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today reported financial results for the three months and year ended December 31, 2005.
"In 2005, we made significant progress toward our goal of entering clinical development with our internal programs," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer. "We continue to be encouraged by the results of preclinical safety testing for our lead programs -- LG617 for Alzheimer`s and cognitive disorders and LG103 for irritable bowel syndrome."
Revenues: Lexicon`s revenues for the three months ended December 31, 2005 increased 30 percent to $33.9 million from $26.0 million for the corresponding period in 2004. The increase was primarily attributable to Lexicon`s completion of two performance milestones related to work it is doing in collaboration with Genentech, Inc. that resulted in payments from Genentech totaling $20 million. Revenue recognized under Lexicon`s alliance with Organon and its award from the Texas Enterprise Fund also contributed to the increase in revenue. Revenue in the fourth quarter of 2004 included performance milestone payments from Genentech and Takeda Pharmaceutical Company Limited. For the year ended December 31, 2005, revenues increased 23 percent to $75.7 million from $61.7 million in 2004.
Research and Development Expenses: Research and development expenses for the three months ended December 31, 2005 increased three percent to $23.9 million from $23.1 million for the corresponding period in 2004. For the year ended December 31, 2005, research and development expenses increased three percent to $93.6 million from $90.6 million in 2004.
General and Administrative Expenses: General and administrative expenses for the three months ended December 31, 2005 were $4.3 million, substantially unchanged from the corresponding period in 2004. For the year ended December 31, 2005, general and administrative expenses decreased two percent to $18.2 million from $18.6 million in 2004.
Net Income (Loss): Net income for the three months ended December 31, 2005 was $5.9 million, or $0.09 per share, principally as a result of the performance milestone payments received in the fourth quarter of 2005. This compares favorably to a net loss of $0.5 million, or $0.01 per share, for the corresponding period in 2004. The net loss for the year ended December 31, 2005 decreased to $36.3 million, or $0.57 per share, from a net loss of $47.2 million, or $0.74 per share in 2004.
Cash and Investments: As of December 31, 2005, Lexicon had $99.7 million in cash and investments, including restricted cash and investments, as compared to $90.2 million as of September 30, 2005 and $87.6 million as of December 31, 2004. Cash and investments at December 31, 2005 reflected the receipt in December 2005 of an up-front payment, performance milestones and research funding pursuant to Lexicon`s alliance with Genentech.
"Our financial and business development efforts were highly successful in 2005," said Julia P. Gregory, Lexicon`s executive vice president, corporate development and chief financial officer. "We continue to create long-term value through our alliances, with immediate positive impact on our revenues and cash position. Strategic collaborations and technology contracts and licenses brought in more than $120 million in cash to Lexicon in 2005, thereby providing a strong source of funding during the year."
Year 2005 Highlights
Expansion of alliance with Genentech: In December 2005, Lexicon announced the expansion of its drug discovery alliance with Genentech to include the advanced research, development and commercialization of new biologic drugs. Lexicon will receive a total of $25 million in upfront and milestone payments and research funding during the three-year advanced research portion of the expanded alliance. In this period, Lexicon will conduct advanced research on a broad subset of targets included in Genentech`s Secreted Protein Discovery Initiative (SPDI) program and validated using Lexicon`s proprietary gene knockout technology.
Lexicon may develop and commercialize drugs for up to six of the targets included in the alliance. Genentech retains an option on the potential development and commercialization of these drugs under a cost and profit sharing arrangement, with Lexicon having certain conditional rights to co- promote drugs on a worldwide basis. Genentech is entitled to receive milestone payments in the event of regulatory approval and royalties on net sales of products commercialized by Lexicon outside of a cost and profit sharing arrangement. Lexicon will receive payments from Genentech upon achievement of milestones related to the development and regulatory approval of certain drugs resulting from the alliance that are developed and commercialized by Genentech. Lexicon is also entitled to receive royalties on net sales of these products, provided they are not included in a cost and profit sharing arrangement.
Completion of two performance milestones in Genentech collaboration: Lexicon completed two performance milestones related to work it is doing in collaboration with Genentech and received corresponding payments totaling $20 million. The first of these milestones related to the completion by Lexicon of the analysis of the physiological and behavioral functions of the final set of targets selected from Genentech`s SPDI program under the companies` initial collaboration. The second related to the delivery of data from advanced research already conducted by Lexicon under the expanded alliance.
Alliance with Organon to develop biotherapeutic drugs: In May 2005, Lexicon and Organon, the human healthcare business of Akzo Nobel, announced the formation of a collaboration to jointly discover, develop and commercialize novel biotherapeutics. The alliance encompasses up to 300 genes encoding secreted proteins or potential antibody targets that were jointly selected for the collaboration, including two of Lexicon`s existing biotherapeutics discovery programs. Organon and Lexicon will share costs and responsibility for research, preclinical and clinical activities and will equally benefit from collaboration product revenue. Lexicon received an upfront payment of $22.5 million from Organon in exchange for access to Lexicon`s drug target discovery capabilities and the exclusive right to co- develop biotherapeutic products that modulate the 300 genes selected for the collaboration. Organon will also provide research funding totaling up to $50 million to Lexicon for Organon`s 50% share of the collaboration`s costs during the four-year target function discovery portion of the alliance.
Alliance with XOMA for antibody drug development and commercialization: In June 2005, Lexicon established an alliance with XOMA Ltd. to jointly develop and commercialize antibody drugs for certain targets discovered by Lexicon. During the three-year initial term of the alliance, Lexicon will select at least three targets for submission to the collaboration and XOMA will generate or engineer antibodies that modulate the collaboration`s targets using phage display libraries and its proprietary Human Engineering(TM) technology. Lexicon and XOMA will jointly develop and commercialize novel antibodies directed at these targets and will share the responsibility and costs for research, preclinical, clinical and commercialization activities. Costs and profits will be allocated 65% to Lexicon and 35% to XOMA.
Award from Texas Enterprise Fund: In July 2005, Lexicon announced it was awarded $35 million from the Texas Enterprise Fund for the creation of a knockout mouse embryonic stem cell library containing 350,000 cell lines. Lexicon is creating this new library using its proprietary gene trapping technology for the Texas Institute for Genomic Medicine, a newly formed non- profit institute. In addition, Lexicon will equip the institute with the bioinformatics software required for the management and analysis of data relating to the library.
Contract with National Institutes of Health: In September 2005, Lexicon entered into a three-year contract to provide selected knockout mouse lines and related phenotypic data to the United States National Institutes of Health (NIH). These materials are related to genes that have already been knocked out and analyzed by Lexicon. Lexicon will receive payment from NIH of approximately $4.9 million for NIH`s initial order of knockout mouse lines. Lexicon retains the sole right to provide these materials to commercial entities.
Harvested novel discoveries from Genome5000(TM) program: Lexicon`s Genome5000 program continued to yield new biologically-validated targets for drug discovery. In this program, Lexicon is analyzing 5,000 genes using its proprietary gene knockout technologies and its extensive physiological and behavioral analyses to discover new drug targets from the human genome. To date, Lexicon has completed the analysis of more than sixty percent of these genes and has harvested more than 90 promising targets related to major medical needs.
Lexicon Conference Call:
Dr. Arthur T. Sands and Julia P. Gregory will host a conference call at 11:00 a.m. Eastern Time on Wednesday, February 22, 2006 to review Lexicon`s operating highlights and its financial results for the year ended December 31, 2005 and to discuss the company`s guidance for 2006.
The dial-in number for the conference call is 800-946-0741 (within the United States) or 719-457-2649 (international). The pass code for all callers is 7195604. Investors can access http://www.lexicon-genetics.com/ to listen to a live webcast of the call. The webcast will be archived and available for review through February 27, 2006.
About Lexicon Genetics
Lexicon Genetics is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon is systematically discovering the physiological and behavioral functions of genes to identify potential points of therapeutic intervention, or drug targets. Lexicon makes these discoveries using its proprietary gene knockout technology to model the physiological effects that could be expected from prospective drugs directed against novel targets. The Company has advanced knockout- validated targets into drug discovery programs in six therapeutic areas: diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. Lexicon is working both independently and through strategic collaborations and alliances to accelerate the development and commercialization of its discoveries. Additional information about Lexicon is available through its corporate website, http://www.lexicon-genetics.com/ .
Safe Harbor Statement
This press release contains "forward-looking statements," including statements about Lexicon`s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management`s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon`s ability to successfully conduct preclinical development of its drug candidates and advance such candidates into clinical development, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as those relating to manufacturing, the regulatory process, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon`s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Business - Risk Factors" in Lexicon`s annual report on Form 10-K for the year ended December 31, 2004, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Lexicon Genetics Incorporated Selected Financial Data Consolidated Statements of Operations Data Three Months Ended Year Ended (In thousands, except December 31, December 31, per share data) 2005 2004 2005 2004 (unaudited) (unaudited) Revenues: Collaborative research $33,393 $21,739 $69,567 $49,736 Subscription and license fees 501 4,272 6,113 12,004 Total revenues 33,894 26,011 75,680 61,740 Operating expenses: Research and development 23,854 23,120 93,625 90,586 General and administrative 4,318 4,349 18,174 18,608 Total operating expenses 28,172 27,469 111,799 109,194 Income (loss) from operations 5,722 (1,458) (36,119) (47,454) Interest income 881 440 2,645 1,638 Interest expense (815) (831) (3,280) (2,660) Other income, net 245 1,308 558 1,304 Income (loss) before taxes 6,033 (541) 36,196 47,172 Income tax provision 119 --- 119 --- Net income (loss) $5,914 $(541) $(36,315) $(47,172) Net income (loss) per common share, basic and diluted $0.09 $(0.01) $(0.57) $(0.74) Shares used in computing net income (loss) per common share, basic 64,539 63,449 63,962 63,327 Shares used in computing net income (loss) per common share, diluted 67,317 63,449 63,962 63,327 Consolidated Balance Sheet Data As of As of December 31, December 31, (In thousands) 2005 2004 (unaudited) Cash and investments, including restricted cash and investments of $430 $99,695 $87,558 Property and equipment, net 85,265 84,573 Goodwill 25,798 25,798 Intangible assets other than goodwill, net 640 1,840 Total assets 218,714 211,980 Deferred revenue 81,582 37,592 Current and long-term debt 36,940 37,631 Accumulated deficit (297,430) (261,115) Total stockholders` equity 85,802 121,594
FCMN Contact: bfaulkner@lexgen.com
[posting]20.340.757 von Hugobald am 23.02.06 12:13:09[/posting]@ Hugobald - danke!
Sieht doch gut aus, soweit ich das interpretieren kann.
Interessiert sich hier niemand für diesen Titel?
Ich wäre für Einschätzungen / Beurteilungen dankbar.
Meixnel
Sieht doch gut aus, soweit ich das interpretieren kann.
Interessiert sich hier niemand für diesen Titel?
Ich wäre für Einschätzungen / Beurteilungen dankbar.
Meixnel
Lexicon Genetics Achieves Research Milestone in Takeda Alliance
Thursday March 2, 1:00 am ET
THE WOODLANDS, Texas, March 2 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - News) announced today that Takeda Pharmaceutical Company Limited has selected LG474 for therapeutic development. LG474 is a target that was discovered by Lexicon in its Genome5000(TM) program. Under the terms of the companies` alliance, the selection by Takeda of a target for therapeutic development entitles Lexicon to a $5 million research milestone payment.
ADVERTISEMENT
In July 2004, Lexicon and Takeda entered into an alliance to develop new drugs directed against promising hypertension targets discovered in Lexicon`s Genome5000 program. In this program, Lexicon is using its proprietary gene knockout technology to rapidly discover the functions of 5,000 of the most pharmaceutically important genes in the human genome. Takeda is responsible for the screening, medicinal chemistry, preclinical and clinical development and commercialization of drugs directed against Lexicon`s targets, and bears all related costs.
The financial consideration to Lexicon under the alliance consisted of a $12 million upfront payment and includes research milestone payments for each target selected for therapeutic development and clinical development and product launch milestone payments related to the development and commercialization of drugs resulting from the alliance. Lexicon is also entitled to receive royalties on worldwide sales of drugs commercialized by Takeda.
"We are pleased that, after extensive research, Takeda supports our positive assessment of the value of the LG474 target and is committed to advancing this drug discovery program into development," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Lexicon. "Takeda`s selection of LG474 is an encouraging progression of our alliance toward therapeutic development and further validation of the importance of the targets we are discovering."
"We are pleased to start research study of LG474 as the first target that we have selected under this collaboration with Lexicon Genetics," said Shigenori Ohkawa, Ph.D., general manager of Takeda`s Pharmaceutical Research Division. "We highly expect this research to lead to the discovery of new drugs for cardiovascular diseases."
As a result of this research milestone payment, Lexicon announced that it expects its revenue for the three months ending March 31, 2006 to range from $18 million to $20 million, which is above Lexicon`s original revenue guidance of $13 million to $15 million for the quarter. Lexicon also reiterated its full year 2006 revenue guidance of $78 million to $82 million.
About Lexicon Genetics
Lexicon Genetics is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon is systematically discovering the physiological and behavioral functions of genes to identify potential points of therapeutic intervention, or drug targets. Lexicon makes these discoveries using its proprietary gene knockout technology to model the physiological effects that could be expected from prospective drugs directed against novel targets. The Company has advanced knockout- validated targets into drug discovery programs in six therapeutic areas: diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. Lexicon is working both independently and through strategic collaborations and alliances to accelerate the development and commercialization of its discoveries. Additional information about Lexicon is available through its corporate website, http://www.lexicon-genetics.com .
Safe Harbor Statement
This press release contains "forward-looking statements," including statements about Lexicon`s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management`s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon`s ability to successfully conduct preclinical development of its drug candidates and advance such candidates into clinical development, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as those relating to manufacturing, the regulatory process, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon`s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Business - Risk Factors" in Lexicon`s annual report on Form 10-K for the year ended December 31, 2004, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
--------------------------------------------------------------------------------
Source: Lexicon Genetics Incorporated
Thursday March 2, 1:00 am ET
THE WOODLANDS, Texas, March 2 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - News) announced today that Takeda Pharmaceutical Company Limited has selected LG474 for therapeutic development. LG474 is a target that was discovered by Lexicon in its Genome5000(TM) program. Under the terms of the companies` alliance, the selection by Takeda of a target for therapeutic development entitles Lexicon to a $5 million research milestone payment.
ADVERTISEMENT
In July 2004, Lexicon and Takeda entered into an alliance to develop new drugs directed against promising hypertension targets discovered in Lexicon`s Genome5000 program. In this program, Lexicon is using its proprietary gene knockout technology to rapidly discover the functions of 5,000 of the most pharmaceutically important genes in the human genome. Takeda is responsible for the screening, medicinal chemistry, preclinical and clinical development and commercialization of drugs directed against Lexicon`s targets, and bears all related costs.
The financial consideration to Lexicon under the alliance consisted of a $12 million upfront payment and includes research milestone payments for each target selected for therapeutic development and clinical development and product launch milestone payments related to the development and commercialization of drugs resulting from the alliance. Lexicon is also entitled to receive royalties on worldwide sales of drugs commercialized by Takeda.
"We are pleased that, after extensive research, Takeda supports our positive assessment of the value of the LG474 target and is committed to advancing this drug discovery program into development," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Lexicon. "Takeda`s selection of LG474 is an encouraging progression of our alliance toward therapeutic development and further validation of the importance of the targets we are discovering."
"We are pleased to start research study of LG474 as the first target that we have selected under this collaboration with Lexicon Genetics," said Shigenori Ohkawa, Ph.D., general manager of Takeda`s Pharmaceutical Research Division. "We highly expect this research to lead to the discovery of new drugs for cardiovascular diseases."
As a result of this research milestone payment, Lexicon announced that it expects its revenue for the three months ending March 31, 2006 to range from $18 million to $20 million, which is above Lexicon`s original revenue guidance of $13 million to $15 million for the quarter. Lexicon also reiterated its full year 2006 revenue guidance of $78 million to $82 million.
About Lexicon Genetics
Lexicon Genetics is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon is systematically discovering the physiological and behavioral functions of genes to identify potential points of therapeutic intervention, or drug targets. Lexicon makes these discoveries using its proprietary gene knockout technology to model the physiological effects that could be expected from prospective drugs directed against novel targets. The Company has advanced knockout- validated targets into drug discovery programs in six therapeutic areas: diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. Lexicon is working both independently and through strategic collaborations and alliances to accelerate the development and commercialization of its discoveries. Additional information about Lexicon is available through its corporate website, http://www.lexicon-genetics.com .
Safe Harbor Statement
This press release contains "forward-looking statements," including statements about Lexicon`s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management`s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon`s ability to successfully conduct preclinical development of its drug candidates and advance such candidates into clinical development, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as those relating to manufacturing, the regulatory process, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon`s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Business - Risk Factors" in Lexicon`s annual report on Form 10-K for the year ended December 31, 2004, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
--------------------------------------------------------------------------------
Source: Lexicon Genetics Incorporated
Na nun ist der Widerstand endlich überwunden und der Kurs aus dem Keil nach Norden ausgebrochen.
Geht es jetzt Richtung $ 8,00?
Wer ist noch dabei?
LG / Meixnel
Geht es jetzt Richtung $ 8,00?
Wer ist noch dabei?
LG / Meixnel
Trading Spotlight
Kann doch nicht sein, daß sich außer meiner Wenigkeit niemand für LEXICON interessiert bzw. investiert ist, oder?
Hat wirklich niemand eine Meinung oder Infos zu LEXICON?
Meixnel
Hat wirklich niemand eine Meinung oder Infos zu LEXICON?
Meixnel
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -1,06 | |
| -0,75 | |
| -1,17 | |
| +1,27 | |
| -1,72 | |
| 0,00 | |
| +1,72 | |
| +0,33 | |
| -5,51 | |
| -0,17 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 206 | ||
| 193 | ||
| 115 | ||
| 58 | ||
| 57 | ||
| 52 | ||
| 45 | ||
| 44 | ||
| 37 | ||
| 36 |
